ProNova Preps Its Next-Gen SC360 For Smaller, Cheaper Era Of Proton Therapy
This article was originally published in The Gray Sheet
Executive Summary
The system, which developers hope to launch in the U.S. in 2015 following completion of a 510(k) submission to FDA, will cost about $50 million for a two-room configuration, and the gantry will weigh 15 tons, well under the typical 110-220-ton weight of most systems, according to ProNova.
You may also be interested in...
New Product Briefs: Hearing Device; Volcano’s iFR Modality; St. Jude Pain Device
FDA approved Cochlear Ltd.’s Nucleus Hybrid L24 cochlear implant system, the first implantable device for adults with severe or profound sensorineural hearing loss. Volcano’s instant wave-Free Ratio (iFR) intravascular imaging modality is cleared based on ADVISE II results. More product news.
ASTRO Meeting In Brief
Research and product news from the American Society for Radiation Oncology’s (ASTRO’s) 54th Annual Meeting, held Oct. 28-31 in Boston
Prostate Cancer Radiation Comparisons Support IMRT, Question Proton Therapy
A large Medicare database analysis provides support for intensity-modulated radiation therapy as the standard radiation tool for prostate cancer, while the nascent proton therapy showed no advantages.